Related Experiment Video

Updated: Aug 17, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Chemopotentiation by PARP inhibitors in cancer therapy

Lucio Tentori1, Grazia Graziani

  • 1Department of Neuroscience, University of Rome, Tor Vergata, Via Montpellier 1, 00133 Rome, Italy. tentori@uniroma2.it

Pharmacological Research
|May 25, 2005
PubMed

Insights

Poly(ADP-ribose) polymerases (PARP) are key in DNA repair and genomic stability. New PARP inhibitors show promise in enhancing chemotherapy for resistant cancers and protecting against drug side effects.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Poly(ADP-ribose) polymerases (PARP) regulate critical cellular processes including DNA repair, gene transcription, and cell death.
  • PARP-1 and PARP-2 are specifically activated by DNA strand breaks and play a crucial role in DNA injury repair.

Purpose of the Study:

  • To review recent preclinical studies on novel, potent, and specific Poly(ADP-ribose) polymerase inhibitors.
  • To explore the therapeutic potential of PARP inhibitors in oncology.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of newly synthesized specific and potent PARP inhibitors.

Main Results:

  • PARP inhibitors can restore sensitivity in tumors resistant to DNA-damaging agents like methylating agents or topoisomerase I inhibitors.
  • These inhibitors may offer protection against chemotherapy-induced oxidative stress and subsequent PARP overactivation.
  • Newly synthesized inhibitors demonstrate specificity and potency in preclinical settings.

Conclusions:

  • PARP inhibitors represent a promising pharmacological strategy to enhance the efficacy of DNA-damaging chemotherapeutic agents.
  • Targeting PARP offers potential for treating resistant malignancies and mitigating adverse drug effects.
  • Further preclinical investigation of novel PARP inhibitors is warranted for cancer therapy development.

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...